ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.


Thunnissen E., Lissenberg-Witte B., van den Heuvel M. M., Monkhorst K., Skov B. G., Sorensen J. B., ...More

Lung cancer (Amsterdam, Netherlands), vol.138, pp.13-18, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 138
  • Publication Date: 2019
  • Doi Number: 10.1016/j.lungcan.2019.09.023
  • Journal Name: Lung cancer (Amsterdam, Netherlands)
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.13-18
  • Keywords: non-small cell lung cancer, alk, immunohistochemistry, fluorescence in situ hybridisation, treatment, prognosis, MOLECULAR TESTING GUIDELINE, KINASE INHIBITORS GUIDELINE, OF-AMERICAN-PATHOLOGISTS, LUNG-CANCER PATIENTS, INTERNATIONAL-ASSOCIATION, COPY NUMBER, REARRANGEMENT, IHC, ADENOCARCINOMA, PREVALENCE
  • Gazi University Affiliated: Yes

Abstract

Objective: Metastasized non-small cell lung cancer (NSCLC) with an anaplastic lymphoma kinase (ALK) rearrangement is usually sensitive to a range of ALK-tyrosine kinase inhibitors. ALK-positive NSCLC have been identified in pivotal phase III trials with fluorescence in situ hybridization (ALK FISH +). These tumors are also expressing the fusion product (ALK immunohistochemistry (IHC) +). However, discrepant cases occur, including ALK IHC + FISH-. The aim of this study was to collect ALK IHC + cases and compare within this group response to crizotinib treatment of ALK FISH + cases with ALK FISH- cases.